You are here

DRV/c+RPV/TAF/FTC

Overview

TAF/FTC/RPV+DRV/c is a regimen containing two NRTIs, an NNRTI, and a boosted PI, and is dosed as two pills taken once a day. It does not appear in either the DHHS or IAS guidelines. However, TAF/FTC/RPV is considered an alternative regimen by the DHHS and a recommended regimen for patients who cannot take an INSTI by the IAS.

Recommendations

DHHS: TAF/FTC/RPV+DRV/c is not ranked, but TAF/FTC/RPV is recommended as an intial ART regimen in certain clinical situations if HIV RNA < 100,000 copies/mL and CD4 > 200 cells/mm3. This regimen has potential disadvantages, limitations for use, and/or less supporting data from RCT than recommended regimens.

IAS: TAF/FTC/RPV+DRV/c is not ranked, but TAF/FTC/RPV is a "recommended initial regimen for individuals in whom an INSTI is not an option."

Other Considerations

TAF

  • Equivalent efficacy to TDF, with improved side effect profile and less impact on kidney function and on bone loss [1]
  • Should not be used in patients with CrCl<30

RPV

  • Approved for use in patients with pre-treatment viral loads <100,000 copies/mL and CD4 count >200 cells/mm3
  • Must be taken with food
  • Interacts with many other drugs
  • Should not be taken with a PPI
  • Lowest risk of rash among NNRTI-based therapies, and low risk of metabolic adverse effects
  • Possible side effects include depressive disorders and suicidality

DRV/c

  • Must be taken with food
  • Low risk of virologic failure, even with intermittent use
  • Interacts with many other drugs 
  • Possible side effects include diarrhea, nausea, and headache

Efficacy in Clinical Trials

RPV

Trial Name Drugs Compared Participants Study Results
STaR FTC/TDF/RPV vs. FTC/TDF/EFV 786 tx-naive At 96 weeks, RPV was non-inferior to EFV overall, superior in patients with pre-ART viral loads ≤100,000 copies/mL, and noninferior in those with pre-ART viral loads >100,000 copies/mL. In patients with pre-ART viral loads >500,000 copies/mL, virologic failure was more common in RPV-treated patients. There were more participants with emergent resistance in the RPV arm [2].

ECHO and THRIVE

2 NRTIs plus RPV or EFV 1368 RPV was noninferior to EFV overall. Among participants with a pre-ART viral load >100,000 copies/mL, more RPV-treated participants experienced virologic failure. In participants with virologic failure, NNRTI and NRTI resistance was more frequently identified in those treated with RPV. Among the RPV-treated participants, the rate of virologic failure was greater in those with pre-treatment CD4 counts <200 cells/mm3 [3].

DRV/c

Trial Name Drugs Compared Participants Study Results
N/A 2 NRTIs + DRV/c (single arm) 313, 95% tx-naive At week 48, 81% achieved viral suppression, while 5% discontinued treatment because of adverse events [4].
Study 115 DRV/c vs.DRV/r 62 DRV/c is bioequivalent to DRV/r in healthy volunteers [5].

 

Did we forget a study or make an error?  If so, please click on the "feedback" tab and provide details and comments.

 


References

  1. Citekey 157 not found
  2. Citekey 155 not found
  3. Citekey 156 not found
  4. Citekey 148 not found
  5. Citekey 149 not found